Evidence map›Paper›PMID 42851949›Full record

ArticleACS omega2026

Delivery of Anticancer Gold-Dithiocarbamate via Thiolated Chitosan Nanoparticles.

Maame Abena O Afrifa, Jovita O Daraezinwa, Samuel G Awuah

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Maame Abena O AfrifaDepartment of Biomedical Engineering, University of Kentucky, Lexington, Kentucky 40506, United States.
Jovita O DaraezinwaDepartment of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States.
Samuel G AwuahDepartment of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States.ORCID https://orcid.org/0000-0003-4947-7283

Funding

WKU Lead Faculty AwardP20GM103436 · NIGMS · UNIVERSITY OF LOUISVILLE · PI ERIC C ROUCHKA · 2012 to 2026
$60.1M
Gold-derived Therapeutic Compounds for Disease ApplicationR01CA258421 · NCI · UNIVERSITY OF KENTUCKY · PI AWUAH, SAMUEL GORMAN · 2021 to 2025
$1.7M
NCI NIH HHS R01 CA258421NIGMS NIH HHS P20 GM103436
6 · The paper itself

Abstract

Thiolated chitosan nanoparticles (TCNs) are versatile biomaterials with applications in tissue engineering, coatings, wound healing, and drug delivery. Their biodegradability and ability to conjugate sulfhydryl-containing payloads make TCNs attractive as carriers for controlled therapeutic delivery. However, the nanodelivery of metallodrugs remains challenging because of instability and premature ligand exchange under physiological conditions. Developing robust strategies that enable the delivery of intact metal-based therapeutics is, therefore, of significant interest. Here, we exploit the redox properties of a gold-(III)-dithiocarbamate complex (AuDCN1) to enable the covalent attachment of its sulfhydryl ligand to the thiolated chitosan polymer backbone through disulfide bond formation. Nanoparticles were subsequently prepared via an ionic gelation method to generate AuDCN1-conjugated thiolated chitosan nanoparticles (Au-TCNs). Cargo release was characterized by LC-MS and spectroscopic methods under reducing conditions triggered by l-glutathione, a biologically relevant nucleophile. Biological evaluation demonstrated that Au-TCN nanoparticles exhibit potent activity against triple-negative breast cancer cells, inducing mitochondrial dysfunction through depolarization of the mitochondrial membrane potential and increased levels of mitochondrial reactive oxygen species production. Furthermore, Au-TCN significantly inhibited mammosphere formation in a three-dimensional culture, indicating activity against stem-like tumor cell populations. Collectively, these results highlight thiolated chitosan nanoparticles as a promising redox-responsive platform for delivering gold-based metallodrugs, expanding therapeutic strategies for the treatment of triple-negative breast cancer.

Identifiers

PMID42851949
PMCPMC13647866

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.